Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Trade group sets new member criteria

by Michael McCoy
May 15, 2017 | A version of this story appeared in Volume 95, Issue 20

The board of the trade association Pharmaceutical Research & Manufacturers of America has approved new criteria for membership that emphasizes R&D. The group also eliminated the “associate” category of membership. It now requires all members to have, on average over three years, an R&D-to-sales ratio of 10% or greater and R&D spending of at least $200 million per year. As a result, 22 companies—several of which have been criticized for their drug pricing practices—are no longer members.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.